
|Articles|March 31, 2008
FDA requires REMS plan for 25 drugs, biologics
FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.
Advertisement
In a notice published in the March 27
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
Vaccine Policy in Flux: Stories Pharmacists Need to Follow
3
Pharmacists Are Essential Drivers of Opioid Stewardship Programs
4
Q&A: Pharmacists Help Patients Navigate Pneumococcal Vaccine Options
5






























